Because both EGFR and PDGFR signal through MAP2K2 (MEK2), the latter of which is significantly activated in the recurrent tumors, pharmacological blockade of MAP2K2 activity may be an alternative approach for the treatment of recurrent HPV+ HNSCC. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.